ArticleCancer discovery2020
The KRAS
Open access · bronzeAbstract readCase Reports
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 789 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
789citing papers in PubMed, 4 pooled it
54.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
789 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,249 citations in OpenAlex.
- Organoids in translation: a bench-to-bedside framework for pancreatic cancer precision medicine.Journal of translational medicine · 2026Pooled it
- KRAS G12C inhibitors in KRASFrontiers in immunology · 2026Pooled it
- Quality and accuracy of radiomics models in predicting KRAS status in lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.Frontiers in immunology · 2025Pooled it
- A critical appraisal of structure-based virtual screening, binding free energy methods, and AI-driven molecular design across the evolving computational landscape of drug discovery.Journal of computer-aided molecular design · 2026Review
- Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma.Experimental hematology & oncology · 2026Article
- Review
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- Molecular Mechanisms and Therapeutic Advances in KRAS G12C-Mutant Non-Small Cell Lung Cancer: Toward Mechanism-Guided Longitudinal Management.Cancer innovation · 2026Review
- Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines.Translational lung cancer research · 2026Article
- Engineered subtilisin protease degrades active KRAS in cancer cells leading to differential cell targeting.Research square · 2026Article
- Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England) · 2026Review
- Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations.Journal of medicinal chemistry · 2026Article
- Chemical Genetic Targeting of the LRRK2 GTPase Domain.bioRxiv : the preprint server for biology · 2026Article
- Targeting MAPK Pathways in Skin, Thyroid, and Pancreatic Cancer: A Perspective on Synthetic Inhibitors and Natural Modulators.Advanced biology · 2026Review
- Rewiring KRAS-driven cancers through the ubiquitin-proteasome system: therapeutic opportunities with a focus on deubiquitinase.Experimental & molecular medicine · 2026Review
- Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.Journal of gastrointestinal cancer · 2026Review
- Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption.Nature communications · 2026Article
- Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer.Apoptosis : an international journal on programmed cell death · 2026Article
- KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Medical oncology (Northwood, London, England) · 2026Review
729 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
34 authors at 10 institutions in 1 country.
Jill HallinMirati Therapeutics, Inc., San Diego, California.ORCID https://orcid.org/0000-0002-8443-7116
Lars D EngstromMirati Therapeutics, Inc., San Diego, California.
Lauren HargisMirati Therapeutics, Inc., San Diego, California.
Andrew CalinisanMirati Therapeutics, Inc., San Diego, California.
Ruth ArandaMirati Therapeutics, Inc., San Diego, California.
David M BriereMirati Therapeutics, Inc., San Diego, California.
Niranjan SudhakarMirati Therapeutics, Inc., San Diego, California.
Vickie BowcutMirati Therapeutics, Inc., San Diego, California.
Brian R BaerArray BioPharma Inc., Boulder, Colorado.
Joshua A BallardArray BioPharma Inc., Boulder, Colorado.
Michael R BurkardArray BioPharma Inc., Boulder, Colorado.
Jay B FellArray BioPharma Inc., Boulder, Colorado.
John P FischerArray BioPharma Inc., Boulder, Colorado.
Guy P VigersArray BioPharma Inc., Boulder, Colorado.
Yaohua XueMemorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0003-1192-1836
Sole GattoMonoceros Biosystems LLC, San Diego, California.ORCID https://orcid.org/0000-0003-3479-418X
Julio Fernandez-BanetMonoceros Biosystems LLC, San Diego, California.
Adam PavlicekMonoceros Biosystems LLC, San Diego, California.
Karen VelastaguiMirati Therapeutics, Inc., San Diego, California.
Richard C ChaoMirati Therapeutics, Inc., San Diego, California.
Jeremy BartonMirati Therapeutics, Inc., San Diego, California.
Mariaelena PierobonGeorge Mason University, Manassas, Virginia.
Elisa BaldelliGeorge Mason University, Manassas, Virginia.ORCID https://orcid.org/0000-0002-6288-4599
Emanuel F PatricoinGeorge Mason University, Manassas, Virginia.
Douglas P CassidyDana-Farber Cancer Institute, Boston, Massachusetts.
Matthew A MarxMirati Therapeutics, Inc., San Diego, California.
Igor I RybkinHenry Ford Medical Center, Detroit, Michigan.
Melissa L JohnsonSarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee.
Sai-Hong Ignatius OuUniversity of California, Irvine, Chao Family Comprehensive Cancer Center, Orange, California.
Piro LitoMemorial Sloan Kettering Cancer Center, New York, New York.
Kyriakos P PapadopoulosSTART Center for Cancer Care, San Antonio, Texas.ORCID https://orcid.org/0000-0002-0667-2620
Pasi A JänneDana-Farber Cancer Institute, Boston, Massachusetts.
Peter OlsonMirati Therapeutics, Inc., San Diego, California.
James G ChristensenMirati Therapeutics, Inc., San Diego, California. christensenj@mirati.com.
Mirati Therapeutics (United States) · USArray BioPharma (United States) · USBell Biosystems (United States) · USGeorge Mason University · USDana-Farber Cancer Institute · USKettering University · USCenter for Health Care Services · USDetroit Medical Center · USTennessee Oncology · USUniversity of California, Irvine Medical Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MWeill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1MDissecting KRAS oncoprotein signaling with small molecule inhibitorsR01CA230745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2018 to 2026
$3.8MStudies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistanceR01CA230267 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LITO, PIRO · 2019 to 2023
$2.0MDissecting the evolution of targeted therapy resistance in BRAFV600E-mutant cancerF30CA232549 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI XUE, JENNY YAOHUA · 2018 to 2021
$191kNCI NIH HHS F30 CA232549NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA230267NCI NIH HHS R01 CA230745NIGMS NIH HHS T32 GM007739
Abstract
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRAS
Indexed as
Disease Models, AnimalMutationAcetonitrilesAdenocarcinoma of LungAnimalsAntineoplastic AgentsApoptosisCell ProliferationClinical Trials, Phase I as TopicFemaleHumansLung NeoplasmsMiceMice, Inbred BALB CMice, Inbred NODMice, NudeAcetonitrilesadagrasibAntineoplastic AgentsKRAS protein, humanPiperazinesProto-Oncogene Proteins p21(ras)PyrimidinesPyrrolidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.